Duloxetine Intermediate and Atorvastatin Intermediates Market Research Report Information by Intermediate (Duloxetine Intermediates, Atorvastatin Intermediates) and Region - Forecast till 2030

Duloxetine Intermediate and Atorvastatin Intermediates Market Overview

The duloxetine intermediate and atorvastatin intermediates market is expected to reach USD 68.12 Million by 2030 at 3.90% CAGR during the forecast period 2022-2030. Duloxetine intermediate is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is widely approved for the treatment of stress urinary incontinence in women, major depressive disorder (MDD), and other chronic diseases. The atorvastatin intermediate is commonly used in lowering the cholesterol level and helps prevent cardiovascular diseases.

Rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, rising incidence of chronic diseases are expected to enhance the duloxetine intermediate and atorvastatin intermediates market growth. However, factors such as increasing healthcare cost and unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.

Market Dynamics

The duloxetine intermediate and atorvastatin intermediates market has been primarily driven by the rising prevalence of major depressive disorder (MOD), the growing importance of generics, increasing demand for atorvastatin intermediate, and growing incidence of chronic diseases. For instance, as per the survey carried out by the American Heart Association and the American College of Cardiology in 2016, around 37.5% (43.2 million) to 48.6% (56 million) of the US adults were on treatment by atorvastatin intermediate. Factors such as rising healthcare cost, unfavorable drug price control policies across various countries may restrain the duloxetine intermediate and atorvastatin intermediates market growth during the forecast period.

Global Duloxetine Intermediate and Atorvastatin Intermediates Market Revenue, by Intermediate, 2017 & 2023 (USD Million)  

Sources: MRFR Analysis

Segmentation

The duloxetine intermediate and atorvastatin intermediates market is segmented into an intermediate type. Based on intermediate, the market is bifurcated into duloxetine intermediates and atorvastatin intermediates. Duloxetine Intermediate segment held a duloxetine intermediate and atorvastatin intermediates market share of 32393.03 USD Million in 2017.

Key Players

The prominent players in the Duloxetine Intermediate and Atorvastatin Intermediates market are Jiangxi Aifeimu Technology Co., Ltd, Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Jigs Chemicals, Manus Aktteva, Arch Pharmalabs, Afine Chemicals Ltd, Shodhana Laboratories, Fluorochem Ltd, Chiral Bio Sciences Ltd, Tokyo Chemical Industry Co., Ltd.

Asia-Pacific Duloxetine Intermediate and Atorvastatin Intermediates Market Share, 2017 (%)       

Sources: MRFR Analysis

Regional Analysis

The duloxetine intermediate and atorvastatin intermediates market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas accounts the largest market share, wherein North America is expected to dominate the market mainly due to the increasing geriatric population and the availability of advanced healthcare facilities in this region.

Europe is anticipated to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are well-established healthcare infrastructure and the increase in adoption of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disease and major mental disorders.

Asia-Pacific is estimated to be the fastest-growing region in the duloxetine intermediate and atorvastatin intermediates market. This can be attributed to developing economies such as China, India, and South Korea emerging as major destinations for the outsourcing of clinical trials, drug manufacturing, and pathology testing. Japan held a market share of 18.5% in 2017.

Also, the duloxetine intermediate and atorvastatin intermediates market in the Middle East and Africa region is projected to account for the least share during the review period. The Middle East is expected to influence the market owing to the increasing use of duloxetine intermediate and atorvastatin intermediates for the treatment of various chronic disorders in Saudi Arabia, Kuwait, and the UAE.

Market Segmentation

Duloxetine Intermediate and Atorvastatin Intermediates Market, by Intermediate Type

• Duloxetine Intermediates


• Atorvastatin Intermediates

Duloxetine Intermediate and Atorvastatin Intermediates Market, by Region

• 
  Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  

• 
  Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • UK
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  

• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• 
  Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Available Additional Customizations

Intended Audience

• Duloxetine intermediate & atorvastatin intermediates manufacturers


• Healthcare providers


• Research institutes and academic centers


• Government associations


• Market research and consulting